Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus
Por:
Montesinos, P, Bergua, J, Infante, J, Esteve, J, Guimaraes, JE, Sierra, J, Sanz, MA
Publicada:
1 nov 2019
Ahead of Print:
1 oct 2019
Resumen:
A significant proportion of adult patients with acute myeloid leukemia (AML) fail to achieve complete remission or will relapse later on after achieving it. Prognosis for relapsed or refractory (R/R) AML patients remains discouraging, with the main curative option still relying on hematopoietic stem cell transplant (HSCT) for those who are eligible. Beyond morphological bone marrow and peripheral blood assessment, evaluation of patient performance status and comorbidities, as well as genetic/molecular characterization, is crucial to make an accurate diagnosis and prognosis, which will be useful to select the most appropriate treatment. Emerging strategies are mainly focusing on the development of immune- and molecular-based approaches. Novel targeted therapies are generally well tolerated, potentially allowing them to be administered alone or in combination with classical chemotherapy agents. Enrolment in clinical trials should be considered first option for R/R AML patients, either as a bridge to HSCT or to benefit from novel therapies that eventually may prolong survival and improve quality of life. An Iberian expert panel has reviewed the recent advances in the management of R/R AML with the aim to develop updated evidence and expert opinion-based recommendations.
Filiaciones:
Montesinos, P:
Hosp Univ & Politecn La Fe, Hematol Dept, Ave Fernando Abril Martorell 106, Valencia 46026, Spain
Inst Salud Carlos III, CIBERONC, Madrid, Spain
Bergua, J:
Hosp San Pedro Alcantara, Div Hematol Oncol, Caceres, Spain
Infante, J:
Ctr Hosp Lisboa Norte, Hosp Santa Maria, Serv Hematol & Transplantacao Medula Ossea, Lisbon, Portugal
Esteve, J:
Hosp Clin Barcelona, IDIBAPS, Dept Hematol, Barcelona, Spain
Guimaraes, JE:
Ctr Hosp Univ Sao Joao, Serv Hematol Clin, Porto, Portugal
Sierra, J:
Autonomous Univ Barcelona, IIB St Pau, Hosp Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Autonomous Univ Barcelona, Jose Carreras Leukemia Res Inst, Barcelona, Spain
Sanz, MA:
Hosp Univ & Politecn La Fe, Hematol Dept, Ave Fernando Abril Martorell 106, Valencia 46026, Spain
|